Bevacizumab (Bev)

DRUG2 trials

Sponsors

Eli Lilly and Company, Fudan University

Conditions

Breast Cancer With Brain MetastasisColorectal CancerHER2-low Expressing Breast Cancer

Phase 2

Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

CompletedNCT00612586

Eli Lilly and CompanyColorectal Cancer

Start: 2008-02-29End: 2011-11-30Updated: 2020-07-21

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Not yet recruitingNCT07150208

Fudan UniversityBreast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer

Start: 2025-09-30End: 2028-09-30Target: 140Updated: 2025-09-02